September–October 2024 – Phase II Clinical Trials Underway

In this critical clinical validation stage, Adapet initiated multi-week trials with 5–10 diabetic dogs and cats, using the CGM device in daily living conditions while collecting comparative BGM data. The trials monitored continuous glucose curve tracking, event-triggered alert precision, and app interaction behavior. Veterinary professionals tracked outcomes including sensor detachment rate, skin reaction profiles, and behavioral tolerance. Data from this phase would be vital for regulatory submissions and academic research contributions.